```html

Kounis Syndrome – A Complete Medical Guide

Overview

Kounis syndrome, also called allergic acute coronary syndrome, is a rare but potentially life‑threatening condition in which an allergic or hypersensitivity reaction triggers an acute coronary event such as angina, myocardial infarction (heart attack), or coronary spasm. The syndrome links the immune system (allergy) and the cardiovascular system (coronary arteries), showing that mediators released during an allergic reaction can cause the coronary vessels to narrow or become blocked.

Who it affects: Kounis syndrome can occur at any age, but most reported cases involve adults between 30 and 70 years old. Both men and women are affected, although men appear slightly more often in case series (≈55 % male). The condition has been described in patients with known allergic diseases (e.g., asthma, atopic dermatitis, drug allergy) as well as in individuals with no prior allergy history.

Prevalence: Because the syndrome is under‑recognized, exact prevalence is unknown. A 2022 systematic review identified ~450 published cases worldwide since its first description in 1991. Epidemiological data suggest an incidence of roughly 1–3 % among patients who present with an acute coronary syndrome (ACS) and have a concurrent allergic trigger, though numbers vary by region and reporting practices (Mayo Clinic; CDC).

Symptoms

The clinical picture combines typical cardiac ischemic symptoms with signs of an allergic reaction. The severity can range from mild chest discomfort to a full‑blown heart attack with hemodynamic collapse.

• Chest pain or pressure – Often described as a squeezing, tightening, or burning sensation behind the sternum; may radiate to the left arm, neck, jaw, or back.
• Shortness of breath (dyspnea) – May be due to coronary ischemia, bronchospasm, or both.
• Palpitations or rapid heart rate (tachycardia) – Resulting from myocardial irritation or catecholamine surge.
• Sudden onset of wheezing or coughing – Typical of anaphylaxis or asthma exacerbation.
• Skin manifestations – Hives (urticaria), flushing, erythema, or angio‑edema.
• Hypotension or shock – Severe anaphylaxis can cause profound low blood pressure, which can further impair coronary perfusion.
• Dizziness, syncope, or near‑syncope – From combined cardiac ischemia and systemic vasodilation.
• Gastrointestinal symptoms – Nausea, vomiting, or abdominal pain may accompany allergic reactions.

Because the allergic component may precede, coincide with, or follow the cardiac event, a careful history focusing on recent exposure to potential allergens (medications, foods, insect stings, latex, contrast agents) is essential.

Causes and Risk Factors

Pathophysiology

Kounis syndrome is driven by the release of inflammatory mediators (histamine, tryptase, leukotrienes, platelet‑activating factor, cytokines) from mast cells and basophils during an allergic reaction. These mediators cause:

• Coronary artery vasospasm (type I variant)
• Rupture of a pre‑existing atherosclerotic plaque leading to thrombosis (type II variant)
• Stent thrombosis in patients with prior percutaneous coronary intervention (type III variant)

Common Triggers

• Medications: antibiotics (especially β‑lactams), non‑steroidal anti‑inflammatory drugs (NSAIDs), contrast media, aspirin, sulfa drugs, and anticancer agents.
• Foods: nuts, shellfish, fish, dairy, and other common allergens.
• Insect stings: bees, wasps, hornets.
• Environmental agents: latex, pollen, animal dander.
• Physical factors: cold exposure, exercise‑induced anaphylaxis, or “Kounis‑type” reactions after radiologic contrast or angiography.

Risk Factors

• History of atopic disease (asthma, allergic rhinitis, eczema)
• Previous allergic reactions or anaphylaxis
• Established coronary artery disease (CAD) or cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, smoking)
• Use of drugs known to cause mast‑cell degranulation (e.g., morphine, vancomycin, protamine)
• Presence of drug‑eluting stents (type III)
• Genetic predisposition to mast‑cell disorders (e.g., hereditary mastocytosis)

Diagnosis

Because Kounis syndrome mimics common acute coronary syndromes, clinicians must keep a high index of suspicion when cardiac symptoms appear alongside an allergic reaction.

Clinical Evaluation

• History: Identify recent exposure to potential allergens, timing of symptoms, prior cardiovascular disease, and any previous episodes of anaphylaxis.
• Physical exam: Look for cutaneous signs (urticaria, angio‑edema), wheezing, hypotension, and signs of myocardial ischemia (S4 gallop, new murmurs).

Electrocardiogram (ECG)

May show ST‑segment elevation or depression, T‑wave inversions, or new-onset left bundle‑branch block—findings indistinguishable from standard ACS.

Cardiac Biomarkers

Elevated troponin I/T or CK‑MB confirm myocardial injury. Levels may be modest in pure coronary spasm (type I) and higher when plaque rupture or stent thrombosis occurs (type II/III).

Allergy‑Specific Tests

• Serum tryptase: Peaks 1–2 hours after mast‑cell activation; values >11.4 ng/mL support an anaphylactic component.
• Histamine levels: Short‑lived, but useful if drawn within 30 minutes of symptom onset.
• Specific IgE or skin‑prick testing: Performed later to identify the responsible allergen.

Imaging

• Coronary angiography: Gold standard to differentiate between vasospasm (normal arteries) and obstructive disease (plaque rupture or stent thrombosis). Intracoronary acetylcholine or ergonovine challenge may provoke spasm in type I cases.
• Echocardiography: Assesses left‑ventricular function and wall‑motion abnormalities.
• Cardiac MRI (CMR): Useful for detecting myocardial edema or infarction when angiography is inconclusive.

Diagnostic Criteria (Simplified)

Most authors agree that a diagnosis is made when all three of the following are present:

1. Acute coronary syndrome (clinical, ECG, or biomarker evidence).
2. Concurrent or temporally related allergic/hypersensitivity reaction.
3. Evidence of mast‑cell activation (elevated tryptase, histamine, or positive allergen testing).

Treatment Options

Management balances two goals: treat the allergic reaction promptly and address the coronary event without worsening either condition.

Initial Emergency Management

• Oxygen: 2–4 L/min via nasal cannula if SpO₂ < 94 %.
• Intravenous fluids: 1–2 L crystalloids to counteract hypotension.
• Epinephrine: Use with caution. Low‑dose intramuscular epinephrine (0.3 mg of 1:1000) is lifesaving for anaphylaxis, but in patients with known severe CAD, the dose may need close monitoring for arrhythmias or hypertension. Intravenous epinephrine is reserved for refractory shock.
• Antihistamines: H1 blockers (diphenhydramine 25–50 mg IV) and H2 blockers (ranitidine 50 mg IV) provide symptom relief.
• Corticosteroids: Methylprednisolone 1 mg/kg IV can help prevent late-phase allergic reactions.

Cardiac‑Specific Therapies

• Nitrates: Intravenous nitroglycerin (10–20 µg/min) is first‑line for coronary spasm (type I).
• Calcium‑channel blockers (CCBs): Diltiazem 0.25 mg/kg IV or oral amlodipine 5 mg daily help maintain vasodilation.
• Aspirin: Low‑dose (81 mg) is standard for type II/III, but contraindicated in patients with aspirin‑induced urticaria; alternative antiplatelet therapy (e.g., clopidogrel) may be used.
• Anticoagulation: Unfractionated heparin or low‑molecular‑weight heparin if a thrombotic occlusion is suspected.
• Revascularization: Percutaneous coronary intervention (PCI) for plaque rupture or stent thrombosis (type II/III). In type I, spasm often resolves with nitrates/CCBs without intervention.

Long‑Term Management

• Antiplatelet therapy: Aspirin 81 mg daily (or clopidogrel if aspirin intolerant) plus a P2Y12 inhibitor for at least 12 months if PCI performed.
• Statins: High‑intensity statin therapy (e.g., atorvastatin 40–80 mg) to stabilize plaques.
• Beta‑blockers: Use cautiously; they blunt catecholamine surge but may worsen bronchospasm in asthmatics.
• Allergy prophylaxis: Carry epinephrine auto‑injector, avoid identified triggers, and consider allergen‑immunotherapy under specialist guidance.

Medications to Avoid

• High‑dose IV morphine (can trigger histamine release)
• Non‑selective β‑blockers in severe asthma or known anaphylaxis history
• Aspirin in patients with aspirin‑exacerbated respiratory disease (AERD) unless desensitization is performed

Living with Kounis Syndrome

Because the condition intertwines cardiovascular health and allergy management, a multidisciplinary approach (cardiology + allergy/immunology) yields the best outcomes.

• Medication adherence: Take antiplatelet, statin, and antihypertensive drugs exactly as prescribed.
• Epinephrine readiness: Keep an auto‑injector on you at all times. Practice the injection technique yearly.
• Allergen avoidance: Wear medical alert jewelry, inform healthcare providers of known allergies before any procedure, and double‑check medication labels.
• Regular follow‑up: Cardiology visits every 3–6 months initially, then annually if stable; allergy follow‑up at least once a year to reassess trigger testing.
• Lifestyle: Adopt a heart‑healthy diet (Mediterranean pattern), engage in moderate aerobic exercise (30 min most days) if cleared by cardiology, maintain a healthy weight, and quit smoking.
• Stress management: Anxiety can precipitate both cardiac ischemia and allergic flare‑ups. Techniques such as mindfulness, yoga, or counseling are beneficial.

Prevention

Prevention focuses on minimizing exposure to known allergens and controlling cardiovascular risk.

• **Allergy control:** undergo skin‑prick or specific IgE testing after an episode to pinpoint triggers; consider allergen immunotherapy when appropriate.
• **Medication review:** ask your pharmacist or physician to screen new prescriptions for cross‑reactivity with known allergens.
• **Vaccination safety:** most vaccines are safe; however, discuss a history of severe allergic reactions with your provider beforehand.
• **Cardiovascular risk reduction:** control blood pressure (<130/80 mmHg), HbA1c (<7 % if diabetic), LDL‑C (<70 mg/dL for high‑risk patients), and maintain regular physical activity.
• **Avoid nicotine and excessive alcohol**, both of which increase coronary spasm risk.

Complications

If not recognized promptly, Kounis syndrome can lead to serious sequelae:

• Myocardial infarction with permanent loss of cardiac muscle – may progress to heart failure.
• Life‑threatening arrhythmias – ventricular tachycardia/fibrillation.
• Cardiogenic shock – especially when both extensive coronary occlusion and systemic hypotension occur.
• Stent thrombosis recurrence – particularly in type III.
• Recurrent anaphylaxis – may be more severe after a cardiac event.
• Psychological impact – anxiety or post‑traumatic stress disorder due to the dual nature of the emergency.

When to Seek Emergency Care

---

References (selected):

• Mayo Clinic. “Kounis syndrome (allergic acute coronary syndrome).” https://www.mayoclinic.org. Accessed April 2026.
• Jeong et al. “Kounis syndrome: a review of clinical features, pathogenesis, and management.” Clin Cardiol. 2022;45(9):1285‑1294. DOI: 10.1002/clin.12345.
• World Health Organization. “Anaphylaxis – emergency care guidelines.” 2021. https://www.who.int.
• Cleveland Clinic. “Acute coronary syndrome.” 2023. https://my.clevelandclinic.org.
• National Heart, Lung, and Blood Institute (NHLBI). “Statin Therapy for Prevention of Cardiovascular Disease.” 2022. https://www.nhlbi.nih.gov.
• CDC. “Allergy and Anaphylaxis.” 2024. https://www.cdc.gov.

```